Navigation Links
New oral drug candidate for African sleeping sickness
Date:12/6/2012

[Geneva, Switzerland, and Kinshasa, Democratic Republic of the Congo 6 December 2012] A new oral-only treatment for sleeping sickness has entered Phase II/III clinical study in patients with late-stage sleeping sickness in the Democratic Republic of the Congo (DRC) and soon in Central African Republic (CAR). The study, initiated by the Drugs for Neglected Diseases initiative (DNDi) and its partners, will test the efficacy and safety of fexinidazole, with once-daily tablets for ten days.

Sleeping sickness or human African trypanosomiasis is fatal without treatment. Spread by the bite of a tsetse fly, the disease threatens the most remote areas of 36 sub-Saharan African countries and, while currently in a period of decline, is known to re-emerge to epidemic levels when surveillance efforts wane. Children below 15 years of age represent nearly a quarter of current patients and DRC alone accounts for the majority of reported cases throughout Africa.

Current treatments for stage 2 of the disease or late stage, when the parasites cross the blood-brain barrier are difficult to administer as they require infusions that are only possible within a hospital infrastructure, in addition to the heavy transport necessary to get them there. Patients living far from this type of structure often have to travel for days, even by foot, to access treatment centres.

'This is a major step in research and development for neglected tropical diseases. It shows that it is possible to bring a new chemical entity through the pipeline to offer an entirely new perspective on tackling a disease like sleeping sickness', comments Dr Bernard Pcoul, DNDi's Executive Director. 'It is by connecting all of our partners in the endemic countries and around the world with the support of engaged donors all with a common goal that we can and will continue to search for adapted treatments for these diseases', he added.

Fexinidazole is the first success of the extensive compound mining efforts pursued by DNDi within the nitroimidazole project initiated in 2005 to explore new and old nitroimidazole drug leads. The objective is to progress fexinidazole through this pivotal Phase II/III study in order to register the drug as a new treatment for stage 2 sleeping sickness caused by the parasite Trypanosoma brucei (T.b.) gambiense, as well as for stage 1 sleeping sickness and sleeping sickness caused by T.b. rhodesiense.

If ultimately successful, fexinidazole would be the first oral treatment to be used for both stage 1 and stage 2 sleeping sickness, thereby replacing the complicated diagnosis and treatment paradigm, which includes systematic lumbar punctures of every diagnosed patient to determine the stage of the disease before deciding which treatment to administer.

'This new chemical entity gives us hope of a drastically simplified way to care for our patients', said Dr Wilfried Mutombo, National Human African Trypanosomiasis Control Programme , DRC, Investigator and Coordinator of the fexinidazole trial. 'In addition, the investments made into renovating the laboratories and hospital wards, training personnel, and introducing adapted technologies that allow us to report in real time on each patient, has elevated an entire group of dedicated professionals to international clinical research standards', he added.

The study was initiated and is conducted by DNDi in collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) and the Human African Trypanosomiasis national control programmes of the Democratic Republic of the Congo and Central African Republic, in addition to collaboration with Mdecins Sans Frontires (MSF). The French pharmaceutical company Sanofi and DNDi co-develop the drug: DNDi is responsible for preclinical, clinical, and pharmaceutical development, while Sanofi is responsible for the industrial development, registration, and production of the drug at its manufacturing sites.

Recruitment for the study will include 510 patients at five clinical sites in DRC and one site in Central African Republic.


'/>"/>
Contact: Violaine Dllenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Related medicine news :

1. Novel drug candidates offer new route to controlling inflammation
2. Presidential candidates should address childhood obesity and bullying, poll says
3. Parc at Piedmont - East Cobb to Host Candidate Forum for Primary Elections
4. New candidate drug stops cancer cells, regenerates nerve cells
5. BWH researchers discover new vaccine candidate for Pseudomonas aeruginosa
6. No Truth to Candidates Claim That Rape Hinders Pregnancy, Experts Say
7. Normal triglyceride levels in people of African descent may hinder diagnosis of metabolic syndrome
8. Can weight loss help African-American breast cancer survivors?
9. Equal access to care helps close survival gap for young African-American cancer patients
10. Systemic sclerosis complications more severe in African Americans than Caucasians
11. Genetic marker may predict smoking quantity in African Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
(Date:2/10/2016)... ... 10, 2016 , ... Workrite Ergonomics this week announced the launch of the ... , “Our goal was to develop a product from the ground up that ... ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The Conform series ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost increases ... D a decade ago, according to The Senior Citizens League (TSCL). ... are coping with rapidly rising costs. “The implications are chilling, particularly for people ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... Body Specialists are delighted to welcome a new addition to their growing practice. ... Body Specialists as a nurse practitioner performing cosmetic procedures including injectables, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... It’s that ... Traci Davis, the new president of the Interscholastic Athletic Association of Maryland (IAAM), Hall ... well how quickly fitness goals are cast aside. , That’s why one of her ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... Florida , February 9, 2016 ... today announced a collaboration with 10x Genomics to ... (NGS), single-cell biology and bioinformatics. --> ... a collaboration with 10x Genomics to develop and ... biology and bioinformatics. --> QIAGEN N.V. ...
(Date:2/9/2016)... , Feb. 9, 2016 Mast Therapeutics, ... clinical-stage therapies for sickle cell disease and heart failure, today ... and warrants to purchase common stock in an underwritten public ... and there can be no assurance as to whether or ... actual size or terms of the offering.   ...
Breaking Medicine Technology: